Literature DB >> 9163853

Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension.

H Suzuki1, M Nakasato, S Sato, S Yokoyama, M Katsuura, S Yamaki, K Hayasaka.   

Abstract

Microangiopathic hemolytic anemia and thrombocytopenia have been reported in patients with primary pulmonary hypertension, but not in patients with congenital heart disease even if accompanied with pulmonary hypertension. We present a 7-year-old boy with atrial septal defect and pulmonary hypertension who developed microangiopathic hemolysis and thrombocytopenia. Microangiopathic hemolytic anemia and thrombocytopenia should be remarked as a complication in patients with congenital heart disease.

Entities:  

Mesh:

Year:  1997        PMID: 9163853     DOI: 10.1620/tjem.181.379

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  4 in total

1.  Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT.

Authors:  Steven M Kawut; Emilia Bagiella; Daichi Shimbo; David J Lederer; Nadine Al-Naamani; Kari E Roberts; R Graham Barr; Wendy Post; Evelyn M Horn; Russell Tracy; Paul Hassoun; Reda Girgis
Journal:  Contemp Clin Trials       Date:  2010-12-10       Impact factor: 2.226

2.  Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.

Authors:  Steven M Kawut; Emilia Bagiella; David J Lederer; Daichi Shimbo; Evelyn M Horn; Kari E Roberts; Nicholas S Hill; R Graham Barr; Erika B Rosenzweig; Wendy Post; Russell P Tracy; Harold I Palevsky; Paul M Hassoun; Reda E Girgis
Journal:  Circulation       Date:  2011-05-18       Impact factor: 29.690

3.  Pulmonary hypertension imitating HELLP syndrome.

Authors:  Adam Morton
Journal:  Obstet Med       Date:  2013-07-25

4.  Platelets in pulmonary hypertension: a causative role or a simple association?

Authors:  Keyhan Sayadpour Zanjani
Journal:  Iran J Pediatr       Date:  2012-06       Impact factor: 0.364

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.